Prosetta signs new DoD contract for medical research (TMTI)
08.17.06 - Prosetta, along with CUBRC as the prime contractor, is awarded a programmatic contract from the Department of Defense to expand research on Prosetta's novel platform for anti-viral diagnostic and therapeutic development. The contract totals approximately $8.3m for first year funding with opportunity for second and third year funding continuation.
